Table 3.
Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and all-cause mortality (n=83)
| Model | MMP-1 | MMP-2 | MMP-3 | MMP-9 | MMP-10 | TIMP-1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p va ue | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| 1 | 1.62 | 1.28; 2.06 | <0.001 | 1.93 | 1.48; 2.51 | <0.001 | 1.82 | 1.38; 2.41 | <0.001 | 1.39 | 1.14; 1.69 | 0.001 | 1.33 | 1.06; 1.67 | 0.015 | 2.10 | 1.55; 2.85 | <0.001 |
| 2 | 1.38 | 1.07; 1.78 | 0.012 | 1.60 | 1.19; 2.15 | 0.002 | 1.39 | 1.05; 1.85 | 0.021 | 1.18 | 0.95; 1.46 | 0.133 | 1.13 | 0.90; 1.41 | 0.313 | 1.39 | 0.97; 1.98 | 0.070 |
| 3 | 1.45 | 1.10; 1.92 | 0.008 | 1.50 | 1.07; 2.09 | 0.017 | 1.32 | 0.95; 1.83 | 0.100 | 1.17 | 0.93; 1.46 | 0.179 | 1.01 | 0.78; 1.30 | 0.943 | 1.15 | 0.75; 1.74 | 0.529 |
| 4 | 1.34 | 1.04; 1.73 | 0.026 | 1.57 | 1.17; 2.10 | 0.002 | 1.40 | 1.06; 1.86 | 0.019 | 1.12 | 0.90; 1.40 | 0.314 | 1.12 | 0.90; 1.41 | 0.316 | 1.29 | 0.89; 1.87 | 0.173 |
| 5 | 1.47 | 1.13; 1.92 | 0.004 | 1.58 | 1.17; 2.12 | 0.002 | 1.41 | 1.07; 1.87 | 0.015 | 1.18 | 0.95; 1.45 | 0.132 | 1.13 | 0.90; 1.41 | 0.307 | 1.33 | 0.93; 1.92 | 0.118 |
HR hazard ratio for all-cause mortality per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
Model 3 Model 2 + eGFR and Ln-UAE
Model 4 Model 2 + inflammatory z-score
Model 5 Model 2 + endothelial dysfunction z-score